Core Viewpoint - The company intends to acquire a 19.0526% stake in Beijing Health from Chengdu Deyixin Huaxin Investment Partnership for 67.56052 million yuan, increasing its ownership in Beijing Health from 80.9474% to 100% [1] Group 1: Acquisition Details - The acquisition will be funded through the company's own or raised funds [1] - The stake corresponds to Chengdu Deyixin's paid-in capital of 67.37 million yuan [1] Group 2: Company Background - Beijing Health was established in December 2020 and serves as the sales and promotion platform for the company's main products [1] - The company focuses on the circulation of high-quality pharmaceuticals in the fields of digestive and anti-infective drugs [1] Group 3: Financial Performance and Strategic Rationale - Beijing Health has achieved profitability and its future profit potential and operational risks are reliably estimable [1] - The acquisition is aimed at optimizing resource allocation, enhancing decision-making efficiency, and promoting synergistic development with quality subsidiaries [1] - This move aligns with the company's long-term development strategy [1]

证券日报网讯2月13日，昆药集团（600422）在互动平台回答投资者提问时表示，公司始终将药品质量 与患者安全放在首位，持续强化全流程质量管控。公司严格遵照国家药品监管法规与GMP规范组织生 产经营，所生产药品均符合法定质量标准。关于股价波动，上市公司股价在二级市场的走势及波动也受 到包括行业政策在内的多重因素影响，敬请投资者注意投资风险。公司始终专注于提升经营质量与核心 竞争力，以稳健经营与长期价值创造回馈股东。 ...

Group 1 - GSK and Ionis have achieved the primary endpoint in the Phase 3 clinical trial of Bepirovirsen for chronic hepatitis B, with plans to submit regulatory filings in Q1 2026 [1] - Merck's subcutaneous formulation of Pembrolizumab has received FDA approval for 2025, with a focus on transitioning patients from intravenous infusion to the new formulation in 2026 [1] - Guangsheng Pharmaceutical's innovative drug GST-HG141 has completed patient enrollment for Phase 3 clinical trials, while Alvotech and Teva's biosimilar Eylea (AVT06) is expected to launch in the U.S. in Q4 2026 [1]

证券日报网讯2月13日，恒瑞医药（600276）在互动平台回答投资者提问时表示，公司坚持科技创新与 国际化发展战略，促进公司业绩可持续增长，以更好的发展回馈股东。公司自主研发的1类创新药硫酸 艾玛昔替尼片已在国内获批，用于成人重度斑秃患者。 ...

智通财经APP获悉，据港交所2月13日披露，普莱医药(江苏)股份有限公司(简称：普莱医药)向港交所主 板递交上市申请，中信证券为其独家保荐人。公司核心产品PL-5于2024年在中国进入监管申报阶段，已 向国家药品监督管理局药品审评中心提交新药上市申请。 毛利 公司简介 招股书显示，普莱医药是一家于2009年4月成立的领先创新型抗菌肽(AMP)治疗药物公司，专注于四个 核心治疗领域，即抗感染、代谢疾病、肿瘤及自身免疫疾病，致力于通过公司的专有突破性技术及候选 药物解决全球重大未被满足的健康需求。截至最后实际可行日期，普莱医药有九种候选药物，包括一种 核心产品(即PL-5)及两种主要产品(即PL-3301及PL-18)。 根据弗若斯特沙利文的数据，公司的核心产品PL-5(培来加南)是首款已在全球提交新药上市申请(NDA) 的加南类药物。凭借创始人于2006年首次共同提出的"膜区分机理"理论，PL-5代表了一种新作用机制， 其肽二级结构折迭以破坏微生物膜的完整性，以应对抗生素耐药 性危机。凭借其抗耐药性、广谱及高 效性的关键优势，PL-5为治疗多重耐药感染提供了突破性的解决方案。其已连续入选国家十二五、十三 五"重 ...

Core Viewpoint - Warner Pharmaceutical (688799) reported a revenue of 1.516 billion yuan for the year 2025, reflecting a year-on-year growth of 7.26%, and a net profit attributable to shareholders of 241 million yuan, which represents a significant increase of 46.95% [1] Group 1 - The increase in revenue is attributed to growth in sales of formulation products, raw materials, intermediates, and technical service income [1] - The rise in net profit is primarily influenced by investment income [1]

Group 1 - The company, Pula Pharmaceutical Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange [1] - The sole sponsor for the listing is CITIC Securities [1]

Core Insights - The year 2025 presents both challenges and opportunities for the Chinese pharmaceutical industry, particularly for Roche China, marking a critical year for structural advancement [1] - Despite a complex external environment, China's improving business climate and supportive innovation policies provide significant opportunities for multinational companies like Roche to deepen their strategic presence in the market [1] Group 1: Company Developments - Roche has invested over 2 billion RMB in Shanghai to establish a new biopharmaceutical production base, marking a milestone in localizing the production of large molecule antibody biologics in China [1] - In the past year, Roche has successfully launched 4 new products or indications in China and included 10 innovative drugs or indications in the national medical insurance directory, enhancing accessibility to innovative therapies for patients [2] - Roche has maintained its position as the fastest-growing among the top five multinational pharmaceutical companies, driven by a strong market performance and a focus on patient needs [2] Group 2: Innovation and Collaboration - Roche has engaged in nearly 10 global exclusive licensing agreements with local innovative pharmaceutical companies, focusing on the development of innovative drugs in oncology and immunology [2] - The company is committed to accelerating the development of China's medical innovation ecosystem, ensuring that more innovative drugs benefit Chinese patients [2] - Roche plans to expand its treatment portfolio in 2026, reinforcing its leadership in oncology and introducing new generation breast cancer drugs, while also advancing in ophthalmology, immunology, nephrology, and neuroscience [3] Group 3: Future Outlook - Roche aims to integrate artificial intelligence and digital technologies across its operations, creating a smart closed-loop system from research and development to patient care [3] - The year 2026 marks Roche's 100th anniversary in China, symbolizing the beginning of a new century of service, with a commitment to making innovative drugs accessible to more patients [3] - The company is dedicated to supporting the "Healthy China 2030" initiative by deepening local collaborations and enhancing its presence in the Chinese market [3]

Group 1 - The year 2025 marks a milestone for the company, celebrating its 15th anniversary and entering a clearer phase in its globalization process [2] - The company achieved significant global growth in the past year, reaching a critical profitability turning point, with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [2] - The company launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotukral), which is now commercially available [2] Group 2 - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [3] - In India, the company's two self-developed products have benefited over 1,500 patients, receiving positive clinical feedback [3] - The company is expanding its global footprint by supporting local commercialization efforts in Indonesia and providing PD-1 inhibitors for clinical trials in sub-Saharan Africa [3] Group 3 - The company's goals for 2026 remain clear: to continue pipeline expansion centered on science and to enhance drug accessibility for patients in more countries [4] - The commitment to making innovations accessible to more patients is seen as a long-term investment and a driving force for the company [4] - The company emphasizes the importance of collaboration with industry partners to gather diverse experiences and wisdom from different regions to improve patient outcomes globally [4]

Core Insights - The year 2025 presents both challenges and opportunities for the Chinese pharmaceutical industry, particularly for Roche China, marking a critical year for structural advancement [2] - Despite a complex external environment, China's continuously improving business climate and supportive innovation policies provide significant opportunities for multinational companies like Roche to deepen their strategic presence in China [2] - Roche has become the second-largest market for the company globally, with over 2 billion RMB invested in a new biopharmaceutical production base in Shanghai, marking a milestone for local production of large molecule biologics [2] Group 1 - In the past year, Roche has successfully launched 4 new products or indications in China and included 10 innovative drugs or indications in the national medical insurance directory, enhancing accessibility to innovative therapies for more patients [3] - Roche ranks first in growth among the top five multinational pharmaceutical companies, driven by a strong market performance and a commitment to addressing patient needs [3] - The company has significantly increased the number of patients benefiting from innovative treatments for influenza, tripling the number compared to the previous year [3] Group 2 - Roche is optimistic about the burgeoning innovation ecosystem in China and has engaged in nearly 10 global exclusive licensing agreements with local innovative pharmaceutical companies to co-develop drugs in oncology and immunology [3] - The company aims to further expand its treatment portfolio by 2026, reinforcing its leadership in oncology and introducing new generation breast cancer drugs, while also advancing in ophthalmology, immunology, nephrology, and neuroscience [4] - Roche plans to integrate artificial intelligence and digital technologies across its operations to create a smart, data-driven ecosystem that enhances the entire patient care process [4] - As one of the earliest foreign pharmaceutical companies in China, Roche is set to celebrate its 100th anniversary in the country in 2026, emphasizing its commitment to benefiting patients and supporting the "Healthy China 2030" initiative [4]